Prosecution Insights
Last updated: May 29, 2026

Examiner: AFREMOVA, VERA

Tech Center 1600 • Art Units: 1653 1657

This examiner grants 51% of resolved cases

Performance Statistics

50.6%
Allow Rate
-9.4% vs TC avg
927
Total Applications
+29.2%
Interview Lift
1315
Avg Prosecution Days
Based on 870 resolved cases, 2023–2026

Rejection Statute Breakdown

6.4%
§101 Eligibility
6.0%
§102 Novelty
78.3%
§103 Obviousness
1.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16604138 ENGINEERED COMMENSAL BACTERIA AND METHODS OF USE Non-Final OA The Regents of the University of California
17955413 PREBIOTIC FORMULATIONS Final Rejection Ohio State Innovation Foundation
17172528 CELL CULTURE STRATEGIES FOR MODULATING PROTEIN GLYCOSYLATION Final Rejection GENENTECH, INC.
18064511 COLORIMETRIC ASSAY FOR HIGH THROUGHPUT, FACILE AND RAPID ANTIMICROBIAL SUSCEPTIBILITIES TESTING Final Rejection Georgia Tech Research Corporation
18022201 Label-free, real-time, whole-cell response monitoring with liquid Raman spectroscopy Final Rejection The Board of Trustees of the Leland Stanford Junior University
18047384 METHOD FOR ESTIMATING CULTURE STATE, INFORMATION PROCESSING DEVICE, AND PROGRAM Final Rejection FUJIFILM Corporation
17879014 REDUCED EMISSIONS USING SYNGAS FERMENTATION Non-Final OA CONOCOPHILLIPS COMPANY
17698257 AGENT FOR PROMOTING COLLAGEN PRODUCTION, MEDICAMENT, COSMETIC, AND METHOD FOR MANUFACTURING AGENT FOR PROMOTING COLLAGEN PRODUCTION Final Rejection Murata Manufacturing Co., Ltd.
17760615 SEAWEED-BASED COMPOSITION Final Rejection Cargill, incorporated
19067759 NOVEL METHOD TO ALTER THE PROTEOME OF A DISEASED HEART BY INJECTION OF ECM PARTICLES PRODUCED FROM DECELLULARIZED 3D MICROTISSUES OF HUMAN MESENCHYMAL STEM CELLS Non-Final OA XM Therapeutics, Inc.
18985909 METHOD FOR ENHANCING IMMUNE SYSTEM FUNCTIONS IN A SUBJECT Final Rejection Macularity, Inc.
17801002 METHODS FOR REHABILITATING HEART FAILURE USING GENE THERAPY Non-Final OA UNIVERSITY OF UTAH RESEARCH FOUNDATION
17608274 FEED COMPOSITIONS CONTAINING BETAINE SALTS Non-Final OA Evonik Operations GmbH
17736430 METHOD FOR PRODUCING COLLAGEN PEPTIDES FROM BONES, AND PRODUCED COLLAGEN PEPTIDES Non-Final OA GELITA AG
15474723 PROBIOTIC COMPOSITIONS AND METHODS Final Rejection CORNELL UNIVERSITY
16866154 POLYHYDROXYALKANOATE PRODUCTION METHOD Final Rejection Newlight Technologies, Inc.
18591819 HOST-BIOME INTERACTIONS Non-Final OA Emulate, Inc.
18532577 MANIPULATION OF TRYPTAMINE METABOLISM Final Rejection Seres Therapeutics, Inc.
17918185 ATTENUATED-BACKGROUND MICROBIOLOGICAL NUTRIENT MEDIA AND METHODS OF USING THE SAME Final Rejection RAPID MICRO BIOSYSTEMS, INC.
17642328 METHODS FOR REDUCTION OF BITTERNESS IN CANNABINOIDS USING MYCELIAL MATERIALS Non-Final OA MYCOTECHNOLOGY, INC.
17640456 Method For Capturing And Purification Of Biologics Final Rejection Amicus Therapeutics, Inc.
18260421 USE OF DEOXYRIBONUCLEASE I IN THE TREATMENT OF ENDOMETRIOSIS IN PATIENTS WITH AN EPIGENETIC SIGNATURE OF ENDOMETRIOSIS ON CELL-FREE DNA Non-Final OA Endolife
17562330 MULTI-SUPPLEMENT COMPOSITIONS Non-Final OA Melaleuca, Inc.
18087112 BIOCONVERSION OF OLEUROPEIN Final Rejection SOCIETE DES PROUITS NESTLES S.A.
17820452 METHOD FOR DETECTION OF ESCHERICHIA COLI AND ANTIBIOTIC RESISTANT BACTERIA IN WATER Non-Final OA EASTERN KENTUCKY UNIVERSITY
17726913 System and Method of Increasing Methane Production in Anaerobic Digesters Final Rejection NCH Corporation
17436280 Chloride-Inducible Prokaryotic Expression System Final Rejection Aurealis Therapeutics AG
17434868 Methods of Screening and Compounds for Adverse Response to an Implant Final Rejection PXD Limited
16985188 PRESERVATION AND TRANSPORT OF AN EX VIVO BIOLOGICAL SAMPLE COMPRISING ULTRASOUND APPLICATION Final Rejection Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month